Form 4: Acurx Pharmaceuticals Director Scodari Acquires Shares and Warrants in Direct Offering

Joseph C. Scodari, a director of Acurx Pharmaceuticals, acquired 24,631 shares of common stock and warrants in a registered direct offering and concurrent private placement.

Summary

• On January 6, 2025, Joseph C. Scodari, a director of Acurx Pharmaceuticals, acquired 24,631 shares of common stock at a price of $1.015 per share.
• The acquisition was part of a registered direct offering by Acurx Pharmaceuticals.
• In a concurrent private placement, Scodari also acquired warrants for 24,631 shares of common stock with an exercise price of $0.90, exercisable from January 7, 2025, and expiring on January 7, 2030.
• Following these transactions, Scodari directly owns 27,708 shares of Acurx Pharmaceuticals common stock and 24,631 warrants.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects a routine transaction. Insider buying can be seen as a positive signal, but it's part of a previously announced capital raise.

Positives

• Director's purchase of shares and warrants signals confidence in the company's future prospects.

Industry Context

This filing reflects insider activity, which is closely monitored by investors for signals about a company's prospects. Direct offerings are a common way for companies, particularly smaller ones like Acurx Pharmaceuticals, to raise capital.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to insider buying.
• The capital raised through the direct offering and private placement could support the company's operations and development programs.

Key Dates